Both effects could explain the higher efficacy of glutaminase inhibitors and alkylating agents in IDH mutant cancer [181,182,183,184,185,186], as well as the best prognosis to temozolomide treatments in IDH, mutated glioma [181,186,187,188]. The gene discussed is IDH2; the disease is glioma.